Literature DB >> 14736491

Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1.

Marie-Cécile Nassogne1, Chantal Lizarraga, Francisca N'Kuli, Françoise Van Bambeke, Roger Van Binst, Pierre Wallemacq, Paul M Tulkens, Marie-Paule Mingeot-Leclercq, Thierry Levade, Pierre J Courtoy.   

Abstract

This paper reports that cocaine may induce a lysosomal storage disorder. Indeed, culture of Rat-1 fibroblasts with 250-500 microM cocaine induced after 2-3 days a major accumulation in lysosomes of electron-dense lamellar structures. By subcellular fractionation, this was reflected by a selective decrease of the buoyant density of several lysosomal enzymes, indicating lysosomal lipid overload. Biochemical analysis confirmed an increased cellular content of major phospholipids and sphingomyelin, but not of cholesterol. Cocaine, a membrane-permeant weak base, is concentrated by acidotropic sequestration, because its accumulation was abrogated by the proton ionophore, monensin and the vacuolar ATPase inhibitor, bafilomycin A1. At its estimated lysosomal concentration, cocaine almost completely inhibited phospholipase A1 activity on liposomes. Cell incubation with cocaine, but not with its inactive metabolite, benzoylecgonine, rapidly inactivated acid sphingomyelinase, as reflected by a 10-fold decrease in Vmax with identical Km. Acid sphingomyelinase inactivation was fully prevented by the thiol proteinases inhibitors, leupeptin and E64, indicating that cocaine induces selective sphingomyelinase proteolysis. Upon cocaine removal, acid sphingomyelinase activity was rapidly restored, pointing to its fast turnover. In contrast, the cellular content of several other lysosomal hydrolases was increased up to 2-fold. Together, these data show that acidotropic accumulation of cocaine in lysosomes rapidly inhibits acid phospholipase A1 and inactivates acid sphingomyelinase, which can explain induction of a mixed lysosomal lipidosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736491     DOI: 10.1016/j.taap.2003.09.026

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

Review 1.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  In vitro exposure of human fibroblasts to local anaesthetics impairs cell growth.

Authors:  C Fedder; B Beck-Schimmer; J Aguirre; M Hasler; B Roth-Z'graggen; M Urner; S Kalberer; A Schlicker; G Votta-Velis; J M Bonvini; K Graetz; A Borgeat
Journal:  Clin Exp Immunol       Date:  2010-09-01       Impact factor: 4.330

Review 3.  The role of sphingolipids in psychoactive drug use and addiction.

Authors:  Liubov S Kalinichenko; Erich Gulbins; Johannes Kornhuber; Christian P Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-01-10       Impact factor: 3.575

4.  Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.

Authors:  Glyn Dawson; Jingdong Qin
Journal:  Biochem Biophys Res Commun       Date:  2010-12-03       Impact factor: 3.575

5.  In vitro effects of cocaine on tunneling nanotube formation and extracellular vesicle release in glioblastoma cell cultures.

Authors:  Chiara Carone; Susanna Genedani; Giuseppina Leo; Monica Filaferro; Kjell Fuxe; Luigi Francesco Agnati
Journal:  J Mol Neurosci       Date:  2014-07-05       Impact factor: 3.444

Review 6.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

7.  Cocaine Modulates the Neuronal Endosomal System and Extracellular Vesicles in a Sex-Dependent Manner.

Authors:  Bryana R Barreto; Pasquale D'Acunzo; Jonathan M Ungania; Sasmita Das; Audrey Hashim; Chris N Goulbourne; Stefanie Canals-Baker; Mitsuo Saito; Mariko Saito; Henry Sershen; Efrat Levy
Journal:  Neurochem Res       Date:  2022-04-30       Impact factor: 4.414

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.